medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 4

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (4)


Dosis atípica de bevacizumab en un paciente con síndrome de Osler-Weber-Rendu

Estrada-Martínez LE, López-Rodríguez WE, García-Ortega GN, Iturbide-Escamilla AE, Chapuli-Azcatl FJ

Idioma: Español
Referencias bibliográficas: 23
Paginas: 649-657
Archivo PDF: 347.06 Kb.


RESUMEN

El síndrome de Osler-Weber-Rendu es una enfermedad de transmisión autosómica dominante. Si bien el síntoma más común es la epistaxis, existen muchas alteraciones viscerales que deben considerarse al momento del estudio. Los anti-VEFG son un pilar en el tratamiento, aunque no existe consenso acerca de la dosis a administrar. Comunicamos el caso de un paciente con síndrome de Osler-Weber-Rendu atendido en el servicio de Medicina Interna del Hospital Regional de Puebla, al que se prescribió una dosis atípica de bevacizumab con buena respuesta terapéutica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of pistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol 2014;5:e91-e95.

  2. Parambil JG. Hereditary hemorrhagic telangiectasia. Clin Chest Med 2016;37:513-521.

  3. Epperla N, Hocking W. Blessing for the bleeder: Bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 2015;13:32-35.

  4. Stellar LI. Heredetary Telangiectasis. N Engl J Med 1942;226:336-338.

  5. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307:948-955.

  6. Combariza JF, Oyala VP. Hereditary hemorrhagic telangiectasia Osler Weber Rendu syndrome and management with bevacizumab. Acta Med Colomb 2015;40:66-68.

  7. Fertoli LF, Lee PL, Lallone L, Barton JC. Intravenous bevacizumab therapy in a patient with hereditary hemorrhagic telangiectasia, ENG E137K, alcoholic cirrhosis, and portal hypertension. Case Rep Gastroenterol 2017;11:293-304.

  8. Lacombe P, Lacout A, Marcy PY, Binsse S, et al. Diagnosis and treatment of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: an overview. Diagnostic and Invertentional. Imaging 2013;94:835-848.

  9. Brinjikji W, Iyer VN, Sorenson T, Lanzino G. Cerebrovascular manifestations of hereditary hemorrhagic telangiectasia. Stroke 2015:46;3329-3337.

  10. Bernabéu C, Blanco FJ, Langa C, Garrido-Martin EM, Botella LM. Involvement of the TGF-β superfamily signalling pathway inhereditary haemorrhagic telangiectasia. J Appl Biomed 2010;8:169-177.

  11. McKusick VA. Telangiectasia, hereditary hemorrhagic, of Rendu, Osler, and Weber; HHT [Internet]. Hamosh A, editor. OMIM. NHGRI; 1986 [cited 2017Sep15]. Available from: https://www.omim.org/entry/187300.

  12. McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P et al. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a ne w era. Front Genet 2015;6:1-8.

  13. Schelker RC, Barreiros AP, Hart C, Herr W, Jung EM. Macro- and microcirculation patterns of intrahepatic blood flow changes in patients with hereditary hemorrhagic telangiectasia. World J Gastroenterol 2017;23:486-495.

  14. Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW. McDonald J, Proctor DD et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48:73-87.

  15. Geisthoff UW, Nguyen HL, Röth A, Seyfert U. How to manage patients with hereditary haemorrhagic telangiectasia. Br J Haematol 2015;171:443-452.

  16. Garg N, Khunger M, Gupta A, Kumar N. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med 2014;5:191-206.

  17. Circo S, Gossage JR. Pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Curr Opin Pulm Med 2014;20:421-428.

  18. Krynytska I, Marushchak M, Mikolenko A, Bob A, Smachylo I, Radetska L et al. Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT). Bosn J Basic Med Sci 2017; Nov 20;17(4):276-285.

  19. Singh S, Swanon KL, Hathcock MA, Kremers WK, Pallanch JF, Krowka MJ et al. Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index. J Hepatol 2014;61:124-131.

  20. Kanellopoulou T, Alexopoulou A. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 2013;13:1315-1326.

  21. Zarrabeitia R, Albiñana V, Salcedo M, Señaris-Gonzalez B, Fernandez-Forcelledo JL, Botella LM. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010;8:473-481.

  22. Ou G, Galoport C, Enns R. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. World J Gastrointest Surg 2016;8:792-795.

  23. Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F et al. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. MAbs 2015;7:630-637.




2020     |     www.medigraphic.com